Recursion

We are a clinical-stage TechBio company decoding biology by integrating technological innovations across biology, chemistry, automation, data science and engineering to industrialize drug discovery. We are leveraging new technology to create virtuous cycles of learning around datasets to build the next-generation biopharmaceutical company. It’s complex biology, decoded. While we are united in a common mission, Decoding Biology to Radically Improve Lives, our greatest strength lies in our differences: expertise, gender, race, disciplines, experience, and perspectives. Deliberately building and cultivating this culture is critical to achieving our audacious goals. We are proudly headquartered in Salt Lake City.

41 S. Rio Grande Street
Salt Lake City, UT 84101
  • Featured Employer

Recursion Decoded tells the story of a new kind of pharma company. One that values big swings over cautious steps. One where the “Bilingual” workforce of “Recursionauts” is made up of a nearly equal balance of technologists and life scientists. And one where we won’t be satisfied with incremental improvements to the status quo. Read about how we are building the biopharma company of the future.
Our Mission

Our mission is to Decode Biology to Radically Improve Lives. Through technologies like automation, new biological tools, and artificial intelligence, we believe we can generate intelligent maps of biology and navigate those maps to more effective medicines.



Historically, it has taken over ten years and an average capitalized R&D cost of approximately $2 billion per approved medicine to move a drug discovery project from early discovery to an approved therapeutic. This failure rate disappoints patients who are waiting for therapy and incurs huge costs that drive up drug prices.

Our Mindset

Our mindset is guided by an unwavering drive to challenge and disrupt the status quo. We diligently guard against complacency, conservatism, risk aversion, and contentment with the familiar. We are not here to make a few medicines. We are here to reimagine how medicines are made.

The recursion mindset is the deep belief and commitment to industrializing drug discovery through automation, algorithms, and data to deliver on our mission. This is made manifest through our founding principles and is supported by our culture and values.

Join our incredible team of world-class talent, expertise and leadership.

Our rapidly growing team of ~500 Recursionauts is balanced between life scientists and computational and technical experts, creating an environment where empirical data, statistical rigor and creative thinking is brought to bear on the problems we address.
We’re working to solve some of the most meaningful problems facing human health today. Come do the most impactful work of your career at a company that prioritizes belonging, collaboration and career development.
NEWS
The year kicked off with a bang as multiple companies raced to a public listing.
Recursion entered into a billion-dollar “transformational collaboration” with Roche to identify and develop up to 40 new medications for neuroscience and oncology.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Investment funds continue springing up into life sciences companies across the globe. Here’s where the money’s being planted this week.
Recursion Pharma is getting bigger and bigger with its new public offering. The Recursion Pharmaceuticals IPO is anticipated to bring approx $306 million.
It’s March Madness in the life sciences industry, with money pouring in faster than LeBron James on a breakaway. Here’s where the big bucks went this week.
This week, four companies set sights on listing their shares on the stock market in hopes of raising significant funds to support the development of their pipelines and businesses.
Pharma and life sciences companies from across the globe provide updates on their pipelines and business.
Companies strengthen their leadership teams and board with this week’s Movers & Shakers.
JOBS
IN THE PRESS